Danlu

Danlu Pharmaceutical is a China-based biotechnology company focused on the discovery and development of innovative small molecule therapeutics using targeted protein degradation (TPD) technology. The company specializes in the design of molecular glues and PROTACs to address challenging targets in oncology and immunology that are considered "undruggable" by traditional methods. Headquartered in the Suzhou Industrial Park, Danlu leverages a proprietary platform to identify novel E3 ligase ligands and degraders with optimized pharmacological properties. The firm is led by a team of scientists with significant experience in global drug R&D and is backed by prominent venture capital investors such as Legend Capital and GL Ventures. Danlu's mission is to advance a pipeline of first-in-class or best-in-class therapies to improve outcomes for patients with life-threatening diseases. The company is currently in the pre-clinical stage, focusing on lead optimization and candidate selection for its primary programs.